Skip to main content

Advertisement

SpringerLink
Log in

What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Singh N . Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16: 281–287.

    Article  CAS  Google Scholar 

  2. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 851–856.

    Article  CAS  PubMed  Google Scholar 

  3. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freedman RB et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 22: 2811–2815.

    Article  Google Scholar 

  4. Brown F, Banken L, Saywell K, Arum I . Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV and CNV seropositive volunteers. Clin Pharmacokinet 1999; 37: 167–176.

    Article  CAS  PubMed  Google Scholar 

  5. Einsele H, Reusser P, Bornhauser M, Kalhs P, Ehninger G, Hebart H et al. Oral Valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006; 10: 3002–3008.

    Article  Google Scholar 

  6. Winston DJ, Baden LR, Gabriel DA, Emmanovilides C, Shaw LM, Lange WR et al. Pharmacokinetics of Ganciclovir after oral valganciclovir versus Intravenous ganciclovir in Allogeneic Stem Cell Transplant patients with Graft Versus Host Disease of the Gastrointestinal Tract. Biol Blood Marrow Transplant 2006; 12: 635–640.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Bone Marrow Transplantation, Department of Medical and Morphologic Research, University of Udine, Italy

    A Candoni, E Simeone, M Tiribelli & R Fanin

  2. Institute of Hygiene and Epidemiology, DPMSC, University of Udine, Italy

    C Pipan

Authors
  1. A Candoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Simeone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Tiribelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Pipan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Fanin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Candoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Candoni, A., Simeone, E., Tiribelli, M. et al. What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?. Bone Marrow Transplant 42, 207–208 (2008). https://doi.org/10.1038/bmt.2008.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.98

  • Springer Nature Limited

This article is cited by

Search

Navigation